Mahmoud A. Elnaggar

Mahmoud A. Elnaggar

Auto-generated profile, based on publicly available information

Mahmoud A. Elnaggar

Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo 11835, Egypt

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Journal of Tissue Engineering
Verified
Journal Article
Open access
TBTarek Mosaid Bedair
Tarek Mosaid Bedair
MEMahmoud A ElNaggar
Mahmoud A ElNaggar
Yoon Ki JoungYoon Ki Joung
Yoon Ki Joung
Dong Keun HanDong Keun Han
Dong Keun Han
Cardiovascular diseases are considered as one of the serious diseases that leads to the death of millions of people all over the world. Stent implantation has been approved as an easy and promising way to treat cardiovascular diseases. However, in-stent restenosis and thrombosis remain serious problems after stent implantation. It was demonstrated in a large body of previously published literature that endothelium impairment represents a major factor for restenosis. This discovery became the driving force for many studies trying to achieve an optimized methodology for accelerated re-endothelialization to prevent restenosis. Thus, in this review, we summarize the different methodologies opted to achieve re-endothelialization, such as, but not limited to, manipulation of surface chemistry and surface topography.

13 September 2016 in Small
Verified
Journal Article
Closed access
PDF file
MEMahmoud A. Elnaggar
Mahmoud A. Elnaggar
SSSeong Ho Seo
Seong Ho Seo
SGSamy Gobaa
Samy Gobaa
KLKyung Seob Lim
Kyung Seob Lim
IBIn-Ho Bae
In-Ho Bae
Yoon Ki JoungYoon Ki Joung
Yoon Ki Joung

6 February 2017 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
MEMahmoud A. Elnaggar
Mahmoud A. Elnaggar
RSRamesh Subbiah
Ramesh Subbiah
Dong Keun HanDong Keun Han
Dong Keun Han
Yoon Ki JoungYoon Ki Joung
Yoon Ki Joung
Introduction: Nitric oxide (NO) is crucial for body homeostasis at moderate levels, but cytotoxic at high levels, thus making it a potential candidate for anticancer therapies and antibacterial surface coatings. To date, NO use has been limited due to its very short half-life. Many strategies have been utilized in an attempt to control the half-life of NO, including (but not limited to) lipid-based carriers, due to their biocompatibility and versatility. Areas covered: In this review, we discuss the latest studies that aimed to control the release of NO via a variety of lipid-based delivery carriers, such as liposomes (echogenic and normal) and microbubbles. In addition, we discuss the different types of NO donors used to control and target the release of NO. Expert opinion: Achieving a NO releasing lipid-based systems to mimic the natural release rate of NO remains a challenging task. Many promising strategies are still to be tackled, such as NO release supported lipid bilayers using GPx mimicking catalysts instead of vesicles, or the use of lipophillic NO donors such as nitrooleate instead of the conventional hydrophilic NO donors. These new strategies may present us with better alternatives to the previously published systems.

1 May 2012 in Medicinal Chemistry
Verified
Journal Article
Open access
PDF file
MAMohamed A. O. Abdel-Fattah
Mohamed A. O. Abdel-Fattah
MEMahmoud A. M. El-Naggar
Mahmoud A. M. El-Naggar
Rasha RashiedRasha Rashied
Rasha Rashied
BGBernard D. Gary
Bernard D. Gary
GPGary Piazza
Gary Piazza
AAAshraf Abadi
Ashraf Abadi
Two series of compounds with the general formula of 4,6-diaryl-2-oxo-1,2 dihydropyridine-3-carbonitriles and their isosteric imino derivatives were synthesized through a one pot reaction of acetophenone, aldehyde and ammonium acetate with ethyl cyanoacetate or malononitrile, respectively. The synthesized compounds were evaluated for tumor cell growth inhibitory using the human HT-29 colon and MDA-MB-231 breast tumor cell lines. Compound 4-(2- Ethoxyphenyl)-2-imino-6-(4-fluorophenyl)-1,2-dihydropyridine-3 carbonitrile (6) showed IC50 value of 0.70 μM versus HT-29. Meanwhile, compound 4-(2-Hydroxyphenyl)-2-imino-6-(4-fluorophenyl)-1,2-dihydropyridine-3-carbonitrile (4) showed IC50 value of 4.6 μM versus MDA-MB-231. Docking compound 10 to possible molecular targets, survivin and PIM1 kinase showed appreciable interactions with both, which suggest possible targets for the antitumor activity of this novel class of anticancer compounds.

1 December 2019 in Journal of Industrial and Engineering Chemistry
Verified
Journal Article
Closed access
MEMahmoud A. Elnaggar
Mahmoud A. Elnaggar
Dong Keun HanDong Keun Han
Dong Keun Han
YJYoon Ki Joung
Yoon Ki Joung

1 May 2012 in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
ISIsmail Salama
Ismail Salama
MAMohamed A. O. Abdel-Fattah
Mohamed A. O. Abdel-Fattah
MHMarwa S. Hany
Marwa S. Hany
SEShaimaa A. El-Sharif
Shaimaa A. El-Sharif
MEMahmoud A. M. El-Naggar
Mahmoud A. M. El-Naggar
AAAshraf Abadi
Ashraf Abadi
Taking advantage of our in-house experimental data on 3-cyano-2-imino-1, 2-dihydropyridine and 3-cyano-2- oxo-1,2-dihydropyridine derivatives as inhibitors of the growth of the human HT-29 colon adenocarcinoma tumor cell line, we have established a highly significant CoMFA and CoMSIA models (q2 cv =0.70/0.639). The models were investigated to assure their stability and predictivity (r2 pred= 0.65/0.61) and successfully applied to design two new potential cell growth inhibitory agents with IC50s in the submicromolar range.